Table 1 Baseline clinicopathologic characteristics of patients who received PIPAC
Malignancy; n (%) | Gastric cancer | 9 (60.0%) |
Ovarian cancer | 6 (40%) | |
Median PCI score (Q1; Q3); | Before PIPAC | 8 (4; 15) |
After PIPAC | 5 (1; 16) | |
Sex; n (%) | Female (n; %) | 11 (73.3%) |
Male (n; %) | 4 (26.7%) | |
Median age (Q1; Q3); years | 58 (51; 68) | |
Median hospitalization (Q1; Q3); days | 5 (3; 6) | |
Median BMI (Q1; Q3) | 25 (20; 30) | |
History of radical surgery for primary tumor; (n; %) | Yes | 8 (53.3%) |
No | 7 (46.7%) | |
Median CA125 level (Q1; Q3); kIU/l | 103 (15; 351) | |
Median CEA level (Q1; Q3); ng/l | 1.4 (0.5; 9.6) | |
Median CA19.9 level (Q1; Q3); ng/l | 12.3 (6.9; 75.9) | |
Number of PIPAC procedures | 1 | 5 (33.3%) |
2 | 2 (13.3%) | |
3–4 | 8 (53.4%) | |
Median operation time (Q1; Q3); min minutes | 115 (110; 133) | |